Ionis Pharmaceuticals (IONS)

Jan 15, 2025, 9:17 AM EST - 2 days ago

Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034

Jan 13, 2025, 8:00 AM EST - 4 days ago

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum

Jan 8, 2025, 4:11 PM EST - 9 days ago

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 7:30 AM EST - 25 days ago

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

Dec 20, 2024, 7:24 AM EST - 4 weeks ago

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

Dec 19, 2024, 6:28 PM EST - 4 weeks ago

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

Dec 19, 2024, 5:18 PM EST - 4 weeks ago

US FDA approves Ionis Pharma's genetic disorder drug

Nov 7, 2024, 7:05 AM EST - 2 months ago

Ionis to present at upcoming investor conferences

Nov 6, 2024, 2:35 PM EST - 2 months ago

Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 7:01 AM EST - 2 months ago

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Nov 6, 2024, 7:00 AM EST - 2 months ago

Ionis reports third quarter 2024 financial results

Nov 4, 2024, 9:44 AM EST - 2 months ago

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE

Oct 23, 2024, 4:25 PM EDT - 3 months ago

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23, 2024, 7:05 AM EDT - 3 months ago

Ionis to hold third quarter 2024 financial results webcast

Oct 21, 2024, 2:08 AM EDT - 3 months ago

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

Oct 3, 2024, 7:00 AM EDT - 3 months ago

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 1, 2024, 7:00 AM EDT - 3 months ago

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease

Sep 10, 2024, 8:32 AM EDT - 4 months ago

Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

HPE RBRK

Sep 9, 2024, 9:10 PM EDT - 4 months ago

Ionis announces pricing of $500.3 million public offering

Sep 9, 2024, 4:20 PM EDT - 4 months ago

Ionis announces proposed public offering of common stock

Aug 11, 2024, 6:51 AM EDT - 5 months ago

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 1, 2024, 4:52 PM EDT - 6 months ago

Ionis Pharmaceuticals, Inc. (IONS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 7:00 AM EDT - 6 months ago

Ionis reports second quarter 2024 financial results

Jul 31, 2024, 9:00 AM EDT - 6 months ago

Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

BIIB

Jul 22, 2024, 1:15 PM EDT - 6 months ago

Ionis Pharmaceuticals, Inc. (IONS) HALOS Study of ION582 in Angelman Syndrome - (Transcript)

Jul 22, 2024, 1:04 PM EDT - 6 months ago

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst

RARE

Jul 22, 2024, 7:00 AM EDT - 6 months ago

Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome

Jul 19, 2024, 8:24 AM EDT - 6 months ago

Ionis to hold second quarter 2024 financial results webcast

Jul 18, 2024, 7:00 AM EDT - 6 months ago

Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease

Jul 8, 2024, 7:05 AM EDT - 6 months ago

Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome

Jun 25, 2024, 6:55 AM EDT - 7 months ago

Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed

Jun 19, 2024, 1:30 AM EDT - 7 months ago

M&A Is Back. 4 Stocks That Could Be Targets.

AMGN BMY XBI

Jun 18, 2024, 7:00 AM EDT - 7 months ago

Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema

Jun 17, 2024, 4:09 PM EDT - 7 months ago

Ionis to present at TD Cowen Genetic Medicines & RNA Summit

May 31, 2024, 7:00 AM EDT - 8 months ago

Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema

May 28, 2024, 4:39 PM EDT - 8 months ago

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28, 2024, 7:00 AM EDT - 8 months ago

Ionis to hold donidalorsen Phase 3 data webcast

May 23, 2024, 7:00 AM EDT - 8 months ago

New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)

May 16, 2024, 2:07 PM EDT - 8 months ago

Biogen and Ionis Pharma shares slide as they end development of ALS treatment

BIIB

May 16, 2024, 7:41 AM EDT - 8 months ago

Biogen, Ionis to discontinue development of ALS drug

BIIB

May 16, 2024, 7:30 AM EDT - 8 months ago

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

BIIB

May 16, 2024, 7:00 AM EDT - 8 months ago

Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome

May 15, 2024, 7:05 AM EDT - 8 months ago

Ionis to host 2024 virtual Annual Meeting of Stockholders

May 7, 2024, 5:39 PM EDT - 9 months ago

Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript

May 7, 2024, 7:00 AM EDT - 9 months ago

Ionis reports first quarter 2024 financial results

Apr 25, 2024, 7:00 AM EDT - 9 months ago

Ionis Publishes 2023 Corporate Responsibility Report

Apr 23, 2024, 7:05 AM EDT - 9 months ago

Ionis to hold first quarter 2024 financial results webcast

Apr 7, 2024, 9:48 AM EDT - 10 months ago

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

Mar 28, 2024, 7:05 AM EDT - 10 months ago

Ionis to hold olezarsen Phase 3 data webcast

Mar 25, 2024, 8:18 AM EDT - 10 months ago

Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting